John Rakow - Jun 3, 2022 Form 3 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
SVP, Genl Counsel, Acting CFO
Signature
John Rakow, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Jun 3, 2022
Transactions value $
$0
Form type
3
Date filed
6/10/2022, 04:37 PM
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
holding ADVM Common Stock 58.2 K Jun 3, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ADVM Stock Option (Right to Buy) Jun 3, 2022 Common Stock 125 K $11.72 Direct F1
holding ADVM Stock Option (Right to Buy) Jun 3, 2022 Common Stock 15.5 K $13.44 Direct F2
holding ADVM Stock Option (Right to Buy) Jun 3, 2022 Common Stock 50 K $3.09 Direct F3
holding ADVM Stock Option (Right to Buy) Jun 3, 2022 Common Stock 100 K $1.84 Direct F4
holding ADVM Stock Option (Right to Buy) Jun 3, 2022 Common Stock 75 K $1.39 Direct F5

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of September 9, 2019, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of September 9, 2019, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2 Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 16, 2021, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of February 16, 2021 subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F3 Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of July 15, 2021, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of July 15, 2021 subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F4 Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of December 2, 2021, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of December 2, 2021 subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F5 Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 18, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of February 18, 2022 subject to the Reporting Person's continued service with the Issuer on each such vesting date.